BFRINasdaq

Biofrontera Inc.

Healthcare·Oncology·Commercial·Woburn, MA, United States
Oncology

Biofrontera Inc. (BFRI): 4 pipeline candidates · 1 upcoming catalyst · ~365 mo cash runway · 1 clinical trial. Updated within the last hour.

6.9/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway10.0

364.7 months

Financial Health5.4

D/E 3.08 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth7.2

4 candidates

Catalyst Momentum2.0

1 upcoming, next in ~6382d

Insider SignalN/A

N/A

A transparent, data-derived signal for Biofrontera Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$12.8M

Cash

$6.5M

Quarterly Burn

$70K

Runway

364.7 mo

Revenue

$10.1M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2056
Today~401 mo out
Catalyst within runway

Pipeline (4 candidates)

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

9

Total value held

$287K

HolderSharesValue
geode capital management, llc109,300$88K
vanguard capital management llc104,508$85K
vanguard fiduciary trust co61,697$50K
susquehanna international group, llp38,574$31K
xtx topco ltd22,493$18K
citigroup inc11,837$10K
blackrock, inc.4,622$4K
ubs group ag1,540$1K
sbi securities co., ltd.305$247
1 clinical trial·1 FDA decision·CEO: Dr. Hermann Luebbert Ph.D.

Frequently asked questions

How many drug candidates are in Biofrontera Inc.'s pipeline?

Biofrontera Inc. (BFRI) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Biofrontera Inc.'s lead drug candidate?

Biofrontera Inc.'s most advanced tracked candidate is ameluz (Phase 3) for Actinic Keratosis (Trunk & extremities).

What is Biofrontera Inc.'s next catalyst?

Biofrontera Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: AMELUZ" — expected December 8, 2043.

What is Biofrontera Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Biofrontera Inc. has approximately 364.7 months of cash runway.

What is Biofrontera Inc.'s market capitalization?

Biofrontera Inc.'s market capitalization is approximately $12.8M.

Get the full picture on Biofrontera Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.